Law360, New York (November 02, 2011, 10:01 PM ET) -- Breckenridge Pharmaceutical Inc. on Wednesday accused rival drugmakers UCB Inc. and Kremers Urban Pharmaceuticals Inc. of marketing prescription versions of Breckenridge's generic laxative product, despite a former agreement to stop distributing the drug.
In its complaint filed in New York federal court, Breckenridge alleges that even though UCB had obtained the U.S. Food and Drug Administration’s approval to market prescription laxative product Glycolax in 2004, it had entered into a superceding agreement with the FDA in June 2007 to stop distributing the drug from from December...
Pharm Co. Breckenridge Sues Rivals Over Generic Laxative
To view the full article, take a free trial now.
